

IMPORTANT NAME CHANGE ANNOUNCEMENT

LarotidTM (amoxicillin)

is the new name for Larocin

Since its introduction in March of 1974, Larocin has been prescribed more than a million times by physicians in the United States. In several of these instances, written prescriptions for Larocin have been confused with Lanoxin, Burroughs Wellcome Company's brand of digoxin. Although the reported incidence of such confusion has been extremely low, Roche Laboratories has changed the name of its product to LAROTID (amoxicillin). We hope you will agree that this action is in the best interest of the patient and of everyone concerned.

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Infections due to susceptible strains of the following gram-negative organisms: *H. influenzae*, *E. coli*, *P. mirabilis* and *N. gonorrhoeae*; and gram-positive organisms: streptococci (including *Streptococcus faecalis*), *D. pneumoniae* and non-penicillase-producing *staphylococci*. Therapy may be instituted prior to obtaining results from bacteriological and susceptibility studies to determine causative organisms and susceptibility to amoxicillin.

Contraindications: In individuals with history of allergic reaction to penicillins.

Warnings, Serious and Occasionally Fatal Hypersensitivity (Anaphylactoid) Reactions Reported in Patients on Penicillin Therapy, Although More Frequent Following Parenteral Therapy. Anaphylaxis has occurred in patients on oral penicillins, more likely in individuals with history of sensitivity to multiple allergens. Before therapy, inquire concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens. If allergic reaction occurs, institute appropriate therapy and consider discontinuance of amoxicillin. Serious anaphylactoid reactions require emergency treatment with epinephrine. Administer oxygen and various steroids and airway management, including intubation, as indicated.

Usage in Pregnancy: Safety in pregnancy not

established.

Precautions: As with any potent drug, assess renal, hepatic and hematopoietic function periodically during prolonged therapy. Keep in mind possibility of superinfection with mycotic or bacterial pathogens; if they occur, discontinue drug and/or institute appropriate therapy.

Adverse Reactions: As with other penicillins, adverse reactions will likely be essentially limited to sensitivity phenomena and more likely occur in individuals previously demonstrating penicillin hypersensitivity and those with history of allergy, rash, hay fever or urticaria. Adverse reactions reported as associated with use of penicillins: Gastrointestinal: Nausea, vomiting, diarrhea. Hypersensitivity: Headache, transient maculopapular rash, transient skin rashness-like reaction may be controlled with antihistamines and, if necessary, systemic corticosteroids. Discontinuance of amoxicillin unless condition is believed to be life-threatening and amenable only to amoxicillin therapy. Liver: Moderate rise in SGOT noted, but significance unknown. Hematologic: Systolic Anemia, thrombocytopenia, thrombocytopoenic purpura, eosinophilia, leukopenia, granulocytosis. All are usually reversible on discontinuation of therapy and believed to be hypersensitivity phenomena.

Dosage: Ear, nose, throat, genitourinary tract, skin and soft tissue infections—Adults: 250 mg every 8 hours. Children: 20 mg/kg/day in divided doses every 8 hours; under 6 kg, 1 ml of Pediatric Drops every 8 hours; 6-12 kg, 2 ml of Pediatric Drops every 8 hours. Continue uncomplicated otitis media and urethritis with oral suspension 3 grams on a single oral dose. NOTE: Children weighing less than 8 kg should receive appropriate dose of oral suspension 125 mg or 250 mg/5 ml. Children weighing 20 kg or more should be dosed according to adult recommendations.

Note: In gonorrhea with suspected lesion of syphilis, perform dark-field examinations before amoxicillin therapy and monthly serological tests for at least four months. In chronic urinary tract infections, frequent bacteriologic and clinical appraisals are necessary. Smaller than recommended doses should not be used. In stubborn infections, several weeks' therapy may be required. Except for gout, continue treatment for a minimum of 48-72 hours after patient is asymptomatic or bacterial count is evidenced. Treat hemolytic streptococcal infections for at least 10 days to prevent acute rheumatic fever or glomerulonephritis.

Supplied: Amoxicillin on the trihydrate: Capsules, 250 mg each; 500 mg oral suspension, 125 mg/5 ml and 250 mg/5 ml pediatric drops, 50 mg/ml.



Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

ABC
Med Trib 39
© 1975, Medical Tribune, Inc.
Vol. 16, No. 39
world news of medicine and its practice—fast, accurate, complete
Wednesday, November 5, 1975

Medical Tribune

and Medical News —
Wednesday, November 5, 1975

From Planned Parenthood:

New Guidelines Set For Contraception In Women Over 40

By FRANCES GOODNIGHT
Medical Tribune Staff

New York—What advice about contraception methods should be given to women over 40 in the wake of recent reports from Britain that use of oral contraceptives by older women is linked to an increased risk of myocardial infarction?

The guidelines definitely include making sure that such patients receive full information about the risk-benefit ratio of the agents, says Dr. Louise B. Tyler, vice president for medical affairs of the Planned Parenthood Federation of America.

Dr. Tyler emphasized during an interview with MEDICAL TRIBUNE that the new reports constitute the first documented proof of association between the "pill" and heart attacks.

Afterward, she noted, has been the announcement by the Food and Drug Administration that it plans to revise labeling for oral agents to reflect the recommendations of its obstetrics and gynecology advisory committee that patients over 40 "be made thoroughly aware of the increased risk and be urged to utilize other forms of contraception."

Findings from the British studies indicate that the estimated incidence of isolated myocardial infarction in women aged 40 to 44 is 9.9 per 100,000 users of oral contraceptives compared to 5.6 per 100,000 users in the

Continued on page 12

Transposed Arteries: First Total Correction

By NATHAN HORWITZ
Medical Tribune Staff

DETROIT—The first successful total correction of transposed great arteries was reported here by a Brazilian surgical team.

Overcoming technical problems that have frustrated heart surgeons for more than two decades, the team was able to transfer the position of the coronary


arteries in transposed great vessels and achieve normal blood flow conditions in a 40-day-old infant with a large ventricular septal defect. Dr. A. D. Jatene told the 2nd International Symposium on Cardiac Surgery at the Henry Ford Hospital.

Dr. Jatene is Professor of Surgery at the Cardiology Institute in São Paulo, Brazil.

The achievement was described as a "great technical triumph" by Dr. John W. Kirklin, Professor and Chairman of the Department of Surgery, University of Alabama. He added that Dr. Jatene's procedure offers "a very exciting" surgical approach, especially in patients with a large VSD.

In describing the new procedure, Dr. Dr. Kirklin

Continued on page 20



Schematic presentation of the new procedure for total anatomical correction of transposed great vessels in patients with VSD. Figure (A) shows ascending aorta, presently anterior, pulmonary artery, presently posterior, and the proximal portion of the coronary arteries. Two stilettos in the anterior wall of the pulmonary artery show where the coronary vessels will be sutured. The coronary arteries are excised (B), along with pieces of the aortic wall, and the openings are closed

Major Victory Seen In Capitation Grant Policy Reversal

High Cataract Rate Found in Child Asthmatics on Steroids

Medical Tribune Report

A

little

insurance

at

press

time

↑

making

rounds

at

press

time

↑

New Drug Combination Held Effective Against All Bacteria

Medical Tribune Report

WASHINGTON, D.C.—Development of a new antibacterial combination drug which has proven effective against every bacterial species tested so far, including *Pseudomonas aeruginosa*, was reported here by investigators from the Merck Sharp & Dohme Research Laboratories at a conference sponsored by the American Society for Microbiology.

While the drug has not as yet been studied in man, extensive laboratory and animal tests suggest it may be a potential alternative agent in the treatment of bacterial strains that have acquired a resistance to other antibiotics, the scientists said.

Guarded Reaction

Initial reaction to the report was guarded. Reflecting the opinion of many, Dr. Merrill Snyder, Professor of Medicine in Clinical Microbiology at the University of Maryland School of Medicine in Baltimore, said, "While I commend the investigators on their work, the results are far from applicable to man. The concepts that have been presented are certainly intriguing but whether this will have some practical application remains to be seen."

MK641/MK642, as the drug is currently known, works by inhibiting bacterial cell wall biosynthesis, explained Frederick M. Kahan, discoverer of the

antibacterial combination.

Although bacterial cell wall biosynthesis is also the target of attack of several classes of widely-used antibiotics, including the penicillins and cephalosporins, the new agent is chemically unrelated. It is a fixed ratio combination of 2-deutero-3-fluoro-D-glucine (DFA), a new substance synthesized by Merck scientists, and a derivative of cycloserine (PCS), a 20-year-old antibiotic with limited therapeutic applications.

When combined, the two elements work synergistically to prevent bacteria from synthesizing D-alanine, an indispensable constituent of the cell wall of every type of bacteria, the research team explained.

Development of MK641/MK642 derived from observations that bacteria produce D-alanine through enzymatic conversion of L-alanine and that L-alanine plays a key role in human metabolism, DFA does not. Therefore, the team theorized, an agent which prevented production of only D-alanine would eliminate bacteria in an infected individual without interfering with normal body functioning.

Biochemical analysis of DFA shows that it prevents bacteria from synthesizing the necessary D-alanine. However, DFA in concentrations several times higher than the minimum inhibitory



Japan's Empress Nagako (right rear) looks on as patients at Chicago's Wyle Children's Hospital prepare drip for surgery.

concentration has the paradoxical ability to restore bacteria to normal growth. In a phenomenon called "self-reversal," DFA is used by bacteria in place of the missing D-alanine. Mr. Kahan told the meeting.

The addition of PCS, he continued, successfully prevents bacteria from using DFA and thereby ensures DFA's

Continued on page 19

Careful Drug Use Urged in Intractable Pain

Medical Tribune World Service

FLORENCE, ITALY—The use of adjuvant drugs such as anti-anxiety and narcotic agents in tandem with narcotics when the latter become necessary for relief of intractable pain was recommended here by Dr. Francesco F. Fodes, Professor of Anesthesiology at the Albert Einstein College of Medicine.

"By the judicious combination of these agents, it is possible to provide active, pain-free, and relatively alert days and restful nights for the patient," Dr. Fodes told the First World Congress on Pain Research and Therapy.

Dr. Fodes cautioned against administration of narcotics for painful conditions of limited duration. Pointing out that "even relatively brief" use may cause physical and psychological dependence, he advised that narcotics use in the presence of acute pain be limited to emergency situations (extremities, acute coronary occlusion, etc.) and severe postoperative pain.

The anesthesiologist also emphasized the need to avoid narcotics for as long as possible in patients with chronic pain and relatively long life expectancy.

"All other methods of pain relief, such as the use of analgesics, chemical or surgical interruption of pain pathways, self-induced electrical stimulation of the spinal cord or specific brain areas, and various forms of psychotherapy should be tried before resorting to the chronic administration of narcotics," he said.

But when intractable pain makes the use of narcotics unavoidable, Dr.

Hospital Visitor

Medical Tribune Report



Japan's Empress Nagako (right rear) looks on as patients at Chicago's Wyle Children's Hospital prepare drip for surgery.

stimulating effect on gastrointestinal motility and on bladder tone.

Management Guides

- Start with orally active narcotics—specifically, the less potent compounds like codeine or oxycodone—and increase dosage gradually. With some types of pain, the pain reduction can be poteniated by non-narcotic analgesics.

If untoward side effects develop, try first an orally active agonist-antagonist (such as pentazocine) and subsequently meperidine, methadone, or morphine.

• Try to increase the analgesic effect of narcotics, and diminish their side effects, by giving adjuvant drugs. For example, during the daytime, benefit may be gained by the simultaneous administration of dextroamphetamine sulfate with the narcotic. At night, the combination of the narcotic with a suitable tricyclic agent will produce analgesia and sleep with less respiratory depression than that encountered after larger doses of narcotics used alone.

In the presence of fear, anxiety, and depression, employ a combination of narcotics with a suitable psychotropic agent. Tranquillizers often relieve narcotics-induced nausea and vomiting, although they are less effective against such symptoms compared to the psychotropic drugs itself.

But he put the emphasis on comfort because of the rapid progression of pain, anxiety, and who have a short life expectancy, and who have "no pleasure out of life" or the desire to live.

The dose and frequency of administration should be geared to relieving pain, anxiety, even at the cost of reducing life expectancy," he said.

Continued on page 19

Antidotes Listed On Toxic Products Termed Outdated

Medical Tribune Report

DENVER—Many common household products that can be injurious if swallowed or inhaled still carry outdated and possibly harmful information about antidotes on their package labels, a clinical toxicologist warned here.

Dr. Barry H. Rumack, director of the Rocky Mountain Poison Center in Denver General Hospital, cited numerous examples of such faulty medical information, including the directives given on containers of *Drene*, *Parson's Ammonia Easy-Off Oven Cleaner*, and *Johinson Wax Company's Big Watty*.

"The primary problem is that manufacturers of poisons have been improved and upgraded over the years, and many of the companies haven't changed their labels—or at least that portion of their labels—in many years," Dr. Rumack told a conference on childhood care held at Swedish Memorial Hospital.

To provide up-to-date information

for physicians on potential poisons and their treatment, Dr. Rumack and his colleagues have developed a compendium on more than 100,000 products and compounds. Called "Poisindex," the poison information system is now used at some 125 hospitals and emergency rooms.

In the case of *Drene*, Dr. Rumack explained that the antidote directive correctly warns against induction of vomiting if the substance has been swallowed. However, the label also advises giving vinegar or a citrus fruit juice. Since *Drene* is an alkali, the acidic acids in these liquids "may cause an increase in the burning of the mouth or esophagus."

Absolutely Wrong!

The final instruction is to follow the juice with buttermilk or a cooking oil which he calls "absolutely wrong, since it will inhibit the physician's ability to determine the extent of injury and what further treatment is necessary."

When parenteral administration of narcotics becomes necessary for satisfactory pain relief, remember that this is "not necessarily a reason for hospitalization" provided someone is available around the clock at home to give injections and to watch the patient.

Dr. Fodes cautions to transfer to a hospital essential if the patient requires intensive nursing care beyond the resources of the family.

Management of pain in this setting depends on the circumstances, he pointed out. For patients who are not bedridden, he believes the principles governing the use of narcotics should be similar to those advised for care at home.

But he puts the emphasis on comfort because of the rapid progression of pain, anxiety, and who have a short life expectancy, and who have "no pleasure out of life" or the desire to live.

The dose and frequency of administration should be geared to relieving pain, anxiety, even at the cost of reducing life expectancy," he said.

Continued on page 19

Wednesday, November 3, 1976

Wednesday, November 3, 1976

MEDICAL TRIBUNE

Wednesday, November 3, 1976

Individualized Therapy Urged in Breast Cancer

Medical Tribune Report

HOUSTON—"The availability of many different therapies for a given condition reflects the inadequacy of my single modality," said Dr. Charles K. Tashima, Associate Professor of Medicine at the University of Texas Health Science Center at Houston. "Such is the case for breast cancer."

Improvement in treatment can be made by better selecting patients to receive various treatment options: surgery, radiotherapy, endocrine manipulation and chemo-immunotherapy, he told a seminar on the medical management of malignancy sponsored by the M. D. Anderson Tumor Institute.

Dr. Tashima indicated that he favored the Halsted radical mastectomy when the disease is sufficiently limited in extent so that cure is possible. Less extensive surgical procedures, combined with radiotherapy, represent another alternative. The axilla is not usually irradiated if dissection is adequate, though significant risk of recurrent disease in the chest wall, the wall will be irradiated, he said.

Chemo-Immunotherapy

Dr. Tashima emphasized that treatment should be modified to fit an individual patient, with emphasis in initial presentation on surgery and radiotherapy. Chemo-immunotherapy currently used in the treatment consists of FAC-BCG (5-FU, Adriamycin and Cytosine plus BCG) which produces a response in 75 per cent of patients and median remission of 16 months. Dr. Tashima stated.

He does not recommend prophylactic castration in breast cancer patients nor does he suggest taking women off birth control pills. "Patients with functioning ovaries are probably not affected by small additions of hormones, so that birth control pills are usually not implicated in misconstruing women," he said. However, he does recom-

mend a new concept, N.E.D. (no evidence of disease), to formalize this philosophy. If a patient were N.E.D., there would be no symptoms referable to cancer, no physical findings of cancer, and no x-ray, scan or laboratory findings indicating the presence of cancer. To formulate such a classification, the physician would consider extent of disease prior to a specific treatment, treatment type, and duration since treatment.

Such a concept would help to determine the recurrence possibility for various groups. He feels it is important, since adjuvant chemotherapy significantly affects recurrence rates and survival.

He also feels it is a method of categorizing patients according to number of sites involved, amount of tumor, and tumor growth rate would further help

to select patients for appropriate therapy, including those patients for whom no treatment is appropriate.

Significant Risk

"In spite of the aggressive approach we have adopted, all the modalities of therapy carry a significant risk and the side effects of treatment are considerable," Dr. Tashima said. For the patient with a small primary and negative axillary nodes, no radiotherapy or adjuvant chemoimmunotherapy is offered, since a radical mastectomy provides a 10-year survival for 80 per cent of patients. He also mentioned the occasional patients with asymptomatic metastatic disease, who have lived with their disease for a number of years. "They appear to have an adequate defense to the tumor and treatment may even be deleterious for these patients."

Though a patient with both primary and metastatic disease may undergo a simple mastectomy, radiotherapy, and chemotherapy, Dr. Tashima again emphasizes his belief in the radical procedure, if the choice is simple and radical. "There's lots of discussion about things that probably won't make a difference in overall survival. But until more data are in, I would go with the radical," he said.

Lung Disease Mortality Dropped in Fuel Shortage

Medical Tribune Report

BERKELEY, CALIF.—The mortality rate from cardiovascular and chronic lung disease decreased substantially in the San Francisco Bay area during last year's nationwide fuel shortage but returned to normal levels when it ended, concluded a study by Dr. Stephen Brown of the U.C.-Berkeley School of Public Health.

When gasoline sales fell nearly 10 per cent around San Francisco, the death rate from such chronic lung diseases as bronchitis, asthma, and emphysema dropped 33 per cent in San Francisco and 38 per cent in less urbanized Alameda County. Heart disease deaths also dropped, by 17 and 11 per cent in the respective areas, he said.

Another instance of an outdated antidote directive, according to Dr. Rumack, is the caution found on the label of most perfume distillates, oils, and other hydrocarbons, to avoid induction of vomiting.

He said that most major poison centers now follow the policy of inducing emesis if the patient has ingested a possibly toxic amount of hydrocarbon. Higher-than-normal peaks of longer-than-normal duration were found after oral glucose administration in 75 per cent of patients with myocardial infarction, he told the International Endocrinology Society meeting here.

In one third of the positive group, the insulin abnormality was the only biochemical defect found after intensive study, according to Dr. V. Karleick, of the department of internal medicine, University Hospital, Plzen, Czechoslovakia. Higher-than-normal peaks of longer-than-normal duration were found after oral glucose administration in 75 per cent of patients with myocardial infarction, he told the International Endocrinology Society meeting here.

The fact that patients usually turn first to the antidotal information on labels when a child ingests or inhales a toxic substance is of particular concern to Dr. Rumack. He recommends that anyone facing a poison emergency contact a poison information center before giving any antidote.

index

CLINICAL NEWS NOTE: "Physicians have a right to refuse to prescribe the [oral contraceptive] agents if in their best judgment after reviewing the history, the physical, and the lab tests they feel the patient's risk is too high. They have to be able to practice according to the dictates of their conscience combined with their best medical judgment." (Dr. Louise B. Tyler, vice president for medical affairs, Planned Parenthood Federation of America. See page 1.)

Medicine: 1, 2, 3, 7, 13, 14

Capitation grant policy reversal seen as major victory 1

Antidotes listed on toxic household products may be outdated 2

Intractable pain management requires judicious use of drugs 2

Experimental drug combination held effective against many bacterial species 2

Colorectal cancer: Little progress in managing this major public health problem 7

Corneal disease can be treated with soft contact lenses. In Consultation 13

Esophageal and renal hypertension may be distinguished from each other by diurnal excretion of Na and H₂O 14**Pediatrics:** 1

High cataract rate found in child asthmatics on curocetide 1

Surgery: 1, 21

Transposed great arteries totally corrected by Brazilian team 1

Recurrent pulmonary emboli may be prevented by "umbrella" filter implanted in inferior vena cava 5

Atectasis after surgery may be prevented by use of "PELIC" bags 21

Risk of hypoxia reduced by hypothermia of brain only 21

feature index

Editorial Columns	6
Letters To Tribune	11
Elliott Juniper	12
John Hawley	14
Consultation	21
Case Report	21
Medical on Stamps	21
Epigram	23
Immucia Medical	23

Medical Tribune

Chair Woodburn, Ph.D.

General Editor

Harry Hennison

Associate Editor

Editorial Staff

Hans Postel

Executive News Editor

William Pritchett

Art Supervisor

Arthur M. Sieker, M.D.

International Publisher

Advisory Board

John Adlai, M.D.

Julian S. Sherman, M.D.

Edward Lowry, M.D.

Albert S. Rubin, M.D.

Alton Ochsner, M.D.

Robert Chase, M.D.

Leo G. Reiter, M.D.

Circulation

880 Third Avenue, New York, N.Y. 10022

Telephone: 421-4000

Circulation audited by Business Publications Audit of Circulation, Inc.

Studies in monkeys of the brain's appetite control centers and the mechanism of safety of immunoreactive plasma insulin has become routine for post infarction patients at the Plzen clinic.

A study of 80 such "insulin risk"

patients showed that a course of graded physical exercise converted the insulin response curve to oral glucose back to normal within six months.

Medical Tribune is published each

Wednesday except on April 30, July 9,

July 26, Aug. 30, Oct. 26 and Dec. 31.

Medical Tribune, Inc., 880 Third Avenue,

New York, N.Y. 10022

Controlled circulation, 100,000

Subscription \$25.00, Students \$7.50.

... brief summaries of editorials or comments in current medical and scientific journals.

The Nondisease Exam

"... If one examines the balance sheet of many physicians . . . the cost benefit to the provider in terms of gross and net income from the periodic health examination or screening procedures may be considerable. Many practitioners have too long set the visit fee as the "loss leader," while profits arise from the many laboratory tests appended onto the routine—or not so routine—visit. Similarly, reimbursement formulas as established by hospitals and third parties are frequently such that the hospital could not afford to do fewer laboratory tests; abolishing the admission screening that Kovin questions might well push sonic already hardpressed institutions further towards the brink!"

"With this kind of economic incentive firmly entrenched, one has to be realistic about chances for making patterns of medical care more appropriate."

"... we must reevaluate the objectives of the periodic health examination . . . we should spend less time and money searching for what is all too often a nondisease." (*Editorial, Thomas L. Deblanco, M.D., and John Noble, M.D., Ann. Int. Med. 83:271, Aug. 1975*)

Neglected Principle

"Most emergency abdominal operations have a clear primary mission: to save a life. Often the patient is a subar surgical risk as a direct result of the condition creating the emergency. A self-evident principle should govern the surgeon's behavior in these situations: the life-threatening condition should be corrected by the safest and simplest means. Yet, at times, otherwise level-headed surgeons seem to depart from this common sense."

"Example: An eighty year old woman correctly undergoes removal of a gangrenous appendix. At the same operation, the surgeon reduces and repairs a large esophageal hiatus hernia suspected from the findings on the chest x-ray film! This is an undeservedly uncomplicated postoperative course, from which the surgeon erroneously infers that he did the patient a favor. He ignores the risk, which might have cost the patient's life, of prolonging the operation, operating through an infected field, and correcting a situation unrelated to the emergency and probably present for years without causing symptoms . . ."

"We all have known surgeons, and not all of them young, with the uncanny destructive instinct to do the one additional thing, that may lengthen the ope rator's agony or lead to post-operative complications and even death. Let us be that surgeon, let us remind ourselves to save life at emergency operations and omit the frills! Who would confront the commercial airline pilot who indulges in aerial acrobatics before safely landing his passenger-filled 747?" (*Editorial, Stanley O. Hoerr, M.D., Amer. J. Surg. 130:1; July, 1975*)

Living better with herself,



Wednesday, November 5, 1975

MEDICAL TRIBUNE

relating better to others.

Disquieting symptoms controlled...

· depression · anxiety · erratic behavior · confusion · hostility · agitation

Navane (thiothixene) helps reduce the frequency and intensity of psychotic manifestations related to chronic brain syndrome, which can erect a barrier between the elderly person and those near and dear to him.

More alert, more active, better able to participate

By effectively relieving such symptoms, Navane helps patients toward a renewed interest in themselves and a revitalized concern for the people and activities around them. And the relative lack of sedation with the use of Navane[®] helps patients remain more alert, more active, and better able to meet the day-to-day demands of life, than prior to treatment.

Well tolerated in the elderly

Even in elderly patients, Navane produces few side effects that necessitate discontinuance of medication. Hypotension, a particularly important problem in the elderly, is relatively infrequent with Navane,^{2,3} as are nonspecific EKG changes.³ Extrapyramidal symptoms may occur but are usually readily controlled. No agranulocytosis has been reported, nor have any cases of clinically confirmed jaundice been attributed to Navane. A division of Pfizer Pharmaceutical Company, New York, New York 10017.

References: 1. NIH, TM, et al.: Scientific Exhibit, presented at the American Public Health Association Convention, Atlantic City, New Jersey, Nov. 12-16, 1972. 2. Birkett, D.H., J. French, W. and Simpson, G.M.: Can. Ther. Res. 14:73, Dec. 3, 1972. 3. Dilleckler, H.L., et al.: Scientific Exhibit, presented at the 22nd Annual Meeting of the American Psychiatric Association, Dallas, Texas, May 1-4, 1972.

Navane[®] (thiothixene)(thiothixene hydrochloride)

Capsules: 1 mg, 2 mg, 5 mg, 10 mg, 20 mg Concentrate 5 mg/ml Intramuscular 2 mg/ml

Usual starting dosage: 2 mg t.i.d. to 5 mg h.i.d.

Navane[®] (thiothixene) Capsules: 1 mg, 2 mg, 5 mg, 10 mg, 20 mg / Navane[®] (thiothixene hydrochloride) Concentrate: 5 mg/ml, Intramuscular 2 mg/ml. Usual starting dosage: 2 mg t.i.d. to 5 mg h.i.d.

PRESCRIBING INFORMATION: Navane[®] (thiothixene) Capsules: 1 mg, 2 mg, 5 mg, 10 mg, 20 mg / Navane[®] (thiothixene hydrochloride) Concentrate: 5 mg/ml, Intramuscular 2 mg/ml. Usual starting dosage: 2 mg t.i.d. to 5 mg h.i.d.

Navane[®] (thiothixene) is a psychotropic agent of the thioether class. It is chemically and pharmacologically similar to the piperazine group of psychotropics. Navane[®] (thiothixene) has been used in the management of psychoses and in the treatment of certain types of psychiatric disorders.

Contraindications: Navane[®] (thiothixene) is contraindicated in patients with glaucoma, cataracts, constrictive pericarditis, and in patients with a history of convulsive disease unless it is used in conjunction with anticonvulsants.

Warnings: Navane[®] (thiothixene) should not be given to patients with a history of convulsive disease unless it is used in conjunction with anticonvulsants.

Usage in Pregnancy: Data on the use of Navane[®] (thiothixene) during pregnancy have not been established. Navane[®] (thiothixene) should not be given to pregnant patients unless the potential benefits to the patient far exceed the possible hazards to the fetus. Patients should be advised to consult their physician before taking Navane[®] (thiothixene).

Usage in Children: The use of Navane[®] (thiothixene) in children under 12 years of age is not recommended because safety and effectiveness have not been established.

Usage in the Elderly: In elderly patients, Navane[®] (thiothixene) should be used with caution because the recommended dosage may be reduced.

Usage in the Paraparetic: As with all psychotropic drugs, Navane[®] (thiothixene) and haloperidol produce extrapyramidal side effects.

Usage in the Psychotic: Navane[®] (thiothixene) should be used only if well tolerated. It should be discontinued if adverse reactions, such as those of the extrapyramidal type, occur.

Usage in the Schizophrenic: Navane[®] (thiothixene) should be used only with caution to avoid extrapyramidal side effects.

Usage in the Depressed: Navane[®] (thiothixene) should not be used in patients with depression.

Usage in the Manic: Navane[®] (thiothixene) should not be used in patients with manic episodes.

Usage in the Epileptic: Navane[®] (thiothixene) should not be used in patients with epilepsy.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Alcoholics: Navane[®] (thiothixene) should not be used in patients with alcoholism.

Usage in the Drug-abusing: Navane[®] (thiothixene) should not be used in patients with drug abuse.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.


Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Usage in the Head-injured: Navane[®] (thiothixene) should not be used in patients with head injuries.

Apresoline®...where the action is in treating hypertension

Apresoline lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of arteriolar smooth muscle.



An antihypertensive idea whose time has come

Doctors who treat hypertension are increasingly interested in the one oral drug that has a mechanism of action exclusively its own—Apresoline.

A propranolol is in an antihypertensive class by itself because it reduces blood pressure through a unique mechanism. Acting at the ultimate site of hypertension, it directly relaxes arterial smooth muscle to decrease peripheral vascular resistance and arterial pressure. As blood pressure falls, there is an accompanying rise in cardiac output and rate.

Apresoline also maintains or increases renal and cerebral blood flow.

Apresoline minimizes postural hypotension

Nickerson¹ describes the action of Apresolin as follows:

"A preferential effect on arterioles, as compared with veins, allows the increase in cardiac output and minimizes postural hypotension; the latter is much less than produced by agents blocking sympathetic nerves."

presoline avoids side effects associated with other agents

Such untoward reactions as drowsiness, lethargy, sedation, sexual dysfunction, and exacerbation of mental depression are not usually encountered with Apranolol. However, as with any antihypertensive agent, hydralazine should be used with caution where advanced renal damage exists.

Apresoline helps tailor the regimen to the patient

When Apresoline is added to an existing anti-hypertensive regimen, it introduces a different and complementary pharmacologic approach to the control of your patient's hypertension.

Apresoline thus affords the physician a variety of combinations with which he can construct regimens more closely molded to individual requirements.

According to Freist such a combination of drugs, each with a different antihypertensive mechanism, is the most effective way to control blood pressure. This may be true in the long run.

Apresoline lends itself admirably to the contemporary antihypertensive rationale and its therapeutic goals: more vigorous and more effective control of blood pressure through a plurality of mechanisms.

**Apresoline: used effectively
in the VA studies**

Appresoline was one of the three basic drugs used in the double-blind VA cooperative studies.^{2,4}

References: 1. Fischman M: Antihypertensive agents and their drug therapy of hypertension. In: McCusker J, Fischman A (eds): *The Pharmacological Basis of Therapeutics*, 4th ed. New York, The Macmillan Company, 1970, p 729, 2, Free Press.

2. Doherty M: Arteriosclerosis as a reversible disease. *Clin Endocrinol (Oxf)* 1970; 51: 101-106.

3. Doherty M: Treatment of mild hypertension in elderly patients in ambulances with the diuretic reserpine (average 15 mg) in 4000 GPs. *Veterans Administration Cooperative Study Group on Antihypertensive Agents*. *JAMA* 1962; 208: 1019-1024.

4. Doherty M: Effect of treatment on morbidity in hypertension. II. Reserpine (average 15 mg) and diuretic (average 90 mg) through 114 months. *Veterans Administration Cooperative Study Group on Antihypertensive Agents*. *JAMA* 1973; 213: 1143-1152, 1970.

Next page: Apresoline (hydralazine) and the Hypertension Task Force

Apresoline® hydrochloride

TABLETS
INDICATIONS: Essential hypertension, alone or as an adjunct.
CONTRAINDICATIONS: Hypertrophic myocardial disease, coronary artery disease, mitral valve disease, pulmonary heart disease.
WARNING: Chronic administration of doses over 200 mg per day may produce an arthritis-like syndrome lead-

ing to a clinical picture simulating acute systemic lupus erythematosus. This may also occur at lower doses. Most of these reactions will resolve upon withdrawal of therapy, but long-term treatment with steroids may be necessary and reduce the risk of relapse many years later. Complete blood counts, L.E. cell preparations and anti-nuclear antibody (ANA) tests should be indicated before and periodically during prolonged therapy. Even though patient is asymptomatic, these tests should be repeated in the presence of any unexplained constitutional changes.

Usage in Pregnancy.
The drug should be used only when, in the
opinion of the physician, it is deemed essential
in the interests of the patient.
ADVERSE REACTIONS:
Use cautiously in suspected coronary artery
disease, cerebrovascular disease, cerebral vein
accidents, and advanced renal disease. Poss-
ible hypotension may occur, and the patient
should be made aware of this possibility.
Skeletal muscle spasm may be reduced;
however, neuromuscular spasticity by paroxysms
of pain may be increased.

and addition of pyridoxine to the regimen if bone marrow depression develops.
Blood dyscrasias, consisting of reduction in granulocytes and red cell counts, agranulocytopenia, agranulocytosis, and aplastic anemia, have been reported rarely. If such abnormalities develop, discontinue therapy. Periodic blood counts are advised during prolonged therapy.

ADVERSE REACTIONS

Common: Headache, drowsiness, irritability; anorexia; constipation; nausea; vomiting; diarrhea.

induced by paresis, incontinence, and temporary dizziness; tremors; muscle cramps; convulsions characterized by depression, tetany, or tetanic spasm; hyperexcitability (including fits of laughter); fever; chills; atrophy of muscles; and, rarely, hemiparesis; constipation, retention in micturition, impotence, gynaecological anomalies, oliguria, polyuria, and circulatory insufficiency in testes and penis; and, in the female, dysmenorrhoea, dyspareunia, and dysuria.

DOSEAGE. Initiate therapy in gradually increasing doses, as just occurring in individual response. Start at 30 mg a dose daily for the first 2 to 4 days, increased to 75 mg a dose daily for better balance of effects. For second and subsequent weeks, dosage is to not exceed a total daily total of 150 mg. The incidence of side effects, particularly T.L.C. cell destruction, is larger in the group of patients receiving larger doses of Altimycin.

including oilseed. In such cases, a major decision must be made as to whether to plant the land in oilseed or in another crop, which may be more profitable. This decision is often based on the current market prices for the different crops.

750 mg, 100 mg (peach, dry-coated); bottles of 100.

CIBA Pharmaceutical Company
Division of CIBA-GEIGY Corporation

CLBA

SPECIFIC SYMPTOM: NONPRODUCTIVE COUGH



SPECIFIC RX:

Hycotuss® EXPECTORANT

Because specific symptoms require specific therapy, Hycotuss® Expectorant was formulated to specifically treat nonproductive cough associated with respiratory tract congestion.

Hycotuss® Expectorant contains hydrocodone bitartrate, a highly effective expectorant, and glycerin/guaifenesin which acts to liquefy and dislodge viscous secretions in the bronchi.

Relieves persistent coughing while it helps liquefy bronchial secretions

HYCOTUSS® is an Endorsed U.S. Trademark. When prescribed by state laws and regulations.

DESCRIPTION

Each Expectorant (6 mL) contains:

Hydrocodone Bitartrate..... 8 mg

Warning: May be habit forming

Glycerin/Guaifenesin..... 100 mg

Hydrochloric Acid..... 10% v/v

Hydrocodone is a centrally acting narcotic antitussive providing cough relief for up to 8 hours. Glycerin/guaifenesin acts as an expectorant by producing increased mucus output from the respiratory tract.

ACTIONS Hydrocodone is a centrally acting narcotic antitussive providing cough relief for up to 8 hours. Glycerin/guaifenesin acts as an expectorant by producing increased mucus output from the respiratory tract.

INDICATIONS Indicated for the symptomatic relief of cough. Especially useful in nonproductive cough associated with respiratory tract congestion.

CONTRAINDICATIONS HYCOTUSS® Expectorant should not be used in patients with hypersensitivity to hydrocodone or glucose.

WARNINGS HYCOTUSS® Expectorant should be prescribed and administered with the same degree of caution appropriate for the use of all oral narcotic-containing medications. Abuse of this product may lead to dependence and loss of the potential for pleasure. Patients should be warned not to drive a car or operate machinery if they become drowsy or dazed after taking this product.

HYCOTUSS® Expectorant Patients receiving narcotics orally, particularly those containing morphine, sedatives, hypnotics, psychosedatives, tranquilizers, antihistamines, and/or other central nervous system depressants should take a reduced dose of HYCOTUSS® Expectorant.


DRUG INTERACTIONS The central nervous system depresses effect of HYCOTUSS® Expectorant may be additive with other centrally acting muscle relaxants, sedatives, hypnotics, psychosedatives, tranquilizers, antihistamines, and/or other central nervous system depressants. See **WARNINGS**.

MANAGEMENT OF OVERDOSE See and Symptom activities while wearing eye glasses. Soft contact lenses have helped to relieve pain and restore

Wednesday, November 5, 1975

Wednesday, November 5, 1975

MEDICAL TRIBUNE



From here on out, the more the rate of inflation jumps, the more it will dry up the liquidity available to everyone.

Roosevelt's purpose in raising the price of gold in the depression of the 1930s was explicitly and unequivocally to undo the ravages of deflation and to start up the corrective momentum of inflation. Roosevelt may have been an economic illiterate—no doubt practical politicians always do—but he grasped the marketplace reality that raising the price of gold primes the pump for inflation—provided liquidity is abundant enough to support the exercise. This was in Roosevelt's time. The opposite is the case now.

Spiraling Interest Rates

The resurgence of inflation is the direct and inescapable reason for the renewed spiraling of interest rates. Today, 7 per cent in tax-exempt income—14 per cent to anyone in a 50 per cent bracket—is no treat for investors willing to tie up money for a year. But money is too scarce and too scared to take advantage of this rate of return. Anytime money is unwilling and unable to accept bonus pay for the privilege of going to work, it's not likely to volunteer for the chance to shun erups in the gold game.

It's little wonder that the very governments which the gold bugs counted on to hold the price of gold are now breaking it. The liquidity crunch is hurting them most. Governments are under the "most urgent and endless pressure to raise cash." The actual announcements of sales from official government holdings are only the tip of the iceberg. No private banks can hope to support the gold market when distress government selling is breaking it.

Ask Janeway

Would you recommend a refined couple invest the majority of their funds in bonds? We are considering BBB-rated utility bonds and long-term Treasury bonds because income is our highest priority. However, this would tie up funds for an extended period of time and would provide only minimum

income.

Medical Couple, M.D. & R.N.

What about conserving your capital? Your thinking would expose you to capital losses as interest rates continue to rise. Retirees may regard themselves as realists in subordinating growth and gain to income, but they are actually being extremely unrealistic. As retirees you will have no chance to earn back any losses this thinking looks you into.

Send your questions on finances, investments, taxes to Janeway, MEDICAL TRIBUNE, 880 Third Avenue, New York, N.Y. 10022

IN CONSULTATION

What's New and Important in Ophthalmology?



The Consultant

DR. ANTONI R. GLASSER
Assistant Professor of Ophthalmology
University of Florida College of Medicine

PERHAPS THE GREATEST ADVANCE in the treatment of corneal disease in over a decade has been the development of the soft contact lens and its use as a "bandage." Innumerable cases of severe blinding keratitis (corneal disease) have been cured or controlled through this relatively simple and inexpensive mode of therapy.

Patients have been treated who had previously undergone almost all known medical and surgical modalities in an unsuccessful attempt to control the disease process or to restore vision.

In the overwhelming majority of cases, soft lens therapy has been able to provide relief of pain, control of the underlying disease process, to promote the healing of damaged and diseased tissue, and, in many cases, to improve or to restore vision.

vision in patients with corneal ulcers, bullous keratopathy (corneal blisters) or "dry" eyes (a painful condition marked by an insufficiency of tears).

Soft lenses have also been useful in correcting aphakia (the result of cataract surgery). Permanent or constant wear of soft contact lenses in aphakia is not new. Since 1969, we and other ophthalmologists have been using the hinged-cut contact lens for permanent wear in a very selective group of aphakic patients. This procedure was reserved for cases where its use was absolutely necessary. However, once the patients were selected, most of them were able to wear the lens continuously, 24 hours a day. Not a patient has been a significant drawback in the fitting of hard contact lenses stems from the fact that most patients that some degree of residual astigmatism quite tolerable if the other refractive errors are corrected.

White corneal scarring is assumed by some to be the main limiting factor in the wear of soft contact lenses, it has actually been a problem in only about 5 to 10 per cent of the population. More important, in fact, is the fluctuation in vision.

These fluctuations are experienced as alternate blurring and clearing of vision. The main cause of vision fluctuation with soft lenses is the fit of the lens. Individual corneas vary in diameter and curvature. Although a soft lens tends to take the shape of the cornea, it may not provide a perfect match even though it may feel comfortable. A poor match with a hard lens would cause corneal swelling, pain and discomfort; with a soft lens it is the sensation that suffers.

If a soft lens is too curved for the cornea, it gets pressed in and out during blinking, causing alternately blurring and clearing of vision. If the cornea is light and superficial, the patient sees a great cloud over all objects. When the edema becomes more marked, the patient will notice brightly colored halos around light. A poorly fitted hard contact lens can cause a great deal of corneal edema in a relatively short time. Even a well fitted hard lens can cause corneal edema or injury of corneal epithelium.

Hard contact lenses are more prone to cause corneal edema than soft. When the cornea is light and superficial, the patient sees a great cloud over all objects. When the edema becomes more marked, the patient will notice brightly colored halos around light. A poorly fitted hard contact lens can cause a great deal of corneal edema in a relatively short time. Even a well fitted hard lens can cause corneal edema or injury of corneal epithelium. On the other hand, soft lenses are almost free of this unpleasant side effect. Soft lenses can be worn during all walking hours either from the first day or very shortly after the beginning of adaptation. Hard lens wearers suffer a loss of tolerance for the lens if they don't wear it on a rather regular basis for quite a few hours every day. The soft lens wearer can abandon the lens for as long as he or she wishes and start wearing it again any time without ill effects. Intermittent social wear is therefore a considerable advantage of this type of lens.

Hard contact lenses, particularly the old, large and thick lenses, when worn for long periods of time can produce a temporary change in the shape of the cornea. Patients are often inconvenienced by this change in shape, particularly the

For routine use of contact lenses, when should the hard contact lens be prescribed? When the soft lens?

This should be the choice of the individual, with the proper fit and consultation of his doctor. For optical reasons, there are persons who will see better with hard or soft contact lenses. Since soft lenses take the shape of the cornea, they tend to reproduce corneal astigmatism without correcting it. In these cases, both eye glasses and hard lenses can correct the blurring of vision caused by corneal astigmatism.

Another type of astigmatism, irregular astigmatism, caused by an irregularity of the natural lens, is corrected only by eye glasses. In many cases, lenticular astigmatism itself corrects corneal astigmatism, eliminating the necessity of correction by necessary lenses. But it is also uncommon to find that elimination of corneal astigmatism by hard contact lenses will result in the production of residual astigmatism or the bringing out of lenticular astigmatism with its blurring of vision.

That this residual astigmatism has not been a significant drawback in the fitting of hard contact lenses stems from the fact that most patients that some degree of residual astigmatism quite tolerable if the other refractive errors are corrected.

White corneal scarring is assumed by some to be the main limiting factor in the wear of soft contact lenses, it has actually been a problem in only about 5 to 10 per cent of the population. More important, in fact, is the fluctuation in vision.

These fluctuations are experienced as alternate blurring and clearing of vision. The main cause of vision fluctuation with soft lenses is the fit of the lens. Individual corneas vary in diameter and curvature. Although a soft lens tends to take the shape of the cornea, it may not provide a perfect match even though it may feel comfortable. A poor match with a hard lens would cause corneal swelling, pain and discomfort; with a soft lens it is the sensation that suffers.

If a soft lens is too curved for the cornea, it gets pressed in and out during blinking, causing alternately blurring and clearing of vision. If the cornea is light and superficial, the patient sees a great cloud over all objects. When the edema becomes more marked, the patient will notice brightly colored halos around light. A poorly fitted hard contact lens can cause a great deal of corneal edema in a relatively short time. Even a well fitted hard lens can cause corneal edema or injury of corneal epithelium.

Hard contact lenses are more prone to cause corneal edema than soft. When the cornea is light and superficial, the patient sees a great cloud over all objects. When the edema becomes more marked, the patient will notice brightly colored halos around light. A poorly fitted hard contact lens can cause a great deal of corneal edema in a relatively short time. Even a well fitted hard lens can cause corneal edema or injury of corneal epithelium. On the other hand, soft lenses are almost free of this unpleasant side effect. Soft lenses can be worn during all walking hours either from the first day or very shortly after the beginning of adaptation. Hard lens wearers suffer a loss of tolerance for the lens if they don't wear it on a rather regular basis for quite a few hours every day. The soft lens wearer can abandon the lens for as long as he or she wishes and start wearing it again any time without ill effects. Intermittent social wear is therefore a considerable advantage of this type of lens.

Hard contact lenses, particularly the old, large and thick lenses, when worn for long periods of time can produce a temporary change in the shape of the cornea. Patients are often inconvenienced by this change in shape, particularly the

New Study of Sclerosis



Dr. Harry Barfield, St. Vincent's Hospital and Medical Center, New York, will coordinate new multidisciplinary study of amyotrophic lateral sclerosis over next two years with NIH funding of \$600,000-plus.

lenses are comfort and ease of adaptation, successful hard contact lens wearers should not be encouraged to switch from hard to soft contact lenses.

What problems do patients have with initial and prolonged use?

After many years and millions of patients wearing contact lenses, both hard and soft lenses have passed the test of time and have proven themselves both safe and effective. Certainly, however, many minor problems still remain with initial and prolonged use of these lenses.

It is said that for every person who successfully adjusts to hard contact lenses, it has actually been a problem in only about 5 to 10 per cent of the population. More important, in fact, is the fluctuation in vision. These fluctuations are experienced as alternate blurring and clearing of vision. The main cause of vision fluctuation with soft lenses is the fit of the lens. Individual corneas vary in diameter and curvature. Although a soft lens tends to take the shape of the cornea, it may not provide a perfect match even though it may feel comfortable. A poor match with a hard lens would cause corneal swelling, pain and discomfort; with a soft lens it is the sensation that suffers.

If a soft lens is too curved for the cornea, it gets pressed in and out during blinking, causing alternately blurring and clearing of vision. If the cornea is light and superficial, the patient sees a great cloud over all objects. When the edema becomes more marked, the patient will notice brightly colored halos around light. A poorly fitted hard contact lens can cause a great deal of corneal edema in a relatively short time. Even a well fitted hard lens can cause corneal edema or injury of corneal epithelium. On the other hand, soft lenses are almost free of this unpleasant side effect. Soft lenses can be worn during all walking hours either from the first day or very shortly after the beginning of adaptation. Hard lens wearers suffer a loss of tolerance for the lens if they don't wear it on a rather regular basis for quite a few hours every day. The soft lens wearer can abandon the lens for as long as he or she wishes and start wearing it again any time without ill effects. Intermittent social wear is therefore a considerable advantage of this type of lens.

Hard contact lenses, particularly the old, large and thick lenses, when worn for long periods of time can produce a temporary change in the shape of the cornea. Patients are often inconvenienced by this change in shape, particularly the

Continued on page

SPECIFIC SYMPTOM: NONPRODUCTIVE COUGH



SPECIFIC RX: **Hycotuss®** EXPECTORANT

Because specific symptoms require specific therapy, Hycotuss® Expectorant was formulated to specifically treat nonproductive cough associated with respiratory tract congestion.

Hycotuss® Expectorant contains hydralazine bitartrate, a highly effective antitussive, and glycerol guadacolate which acts to liquify and dislodge viscous secretions in the bronchi.

Relieves persistent coughing while it helps liquify bronchial secretions

HYCOTUSS® is a trade registered U.S. trademark. *Where permitted by law and regulation.

DESCRIPTION Each teaspoonful (5 ml) contains:

Hydralazine bitartrate..... 6 mg

Warnings: May be habit forming.

Overdosage: Call physician.

Alcohol 10.8% v/v

Hydrocodone 8.8 mg

Warnings: Not for children under 12 years.

Actions: Hydralazine is a centrally acting antitussive, causing nonproductive cough relief for up to 6 hours. Glycerol guadacolate loosens and liquefies thickened and viscous bronchial secretions thereby facilitating its expectoration.

Indications: Indicated for the symptomatic relief of cough due to nonproductive cough associated with upper and lower respiratory tract congestion.

Contraindications: Hycotuss® Expectorant should not be used in patients with hypersensitivity to hydrocodone or codeine.

Warnings: Hycotuss® Expectorant should be prescribed and administered with the same degree of caution as other oral medications containing hydrocodone. Because it can produce drug dependency and tolerance, the potential for abuse, patients should be warned not to take more than directed. Patients should be advised to show impaired mental clarity, physical abilities with taking Hycotuss® Expectorant, other medications, alcohol, sedatives or other central nervous system depressants. These effects may establish an additive central nervous system depression. What such combination may be anticipated should be explained to patient.

Precautions: Use with caution in patients with glaucoma,

hypertension, heart disease, and/or diabetes. If hypertension occurs, seek medical advice immediately.

Do not use if you have a history of asthma, emphysema, chronic bronchitis, or any other respiratory disorder.

Storage and Administration: Hycotuss® Expectorant should be taken after meals and at bedtime, not less than 4 hours apart. Take 1/2 to 1 teaspoonful every 4 hours, as needed. Do not exceed 4 times daily. If necessary, take 1/2 to 1/4 teaspoonful every 2 hours.

Indications: Dosage should be adjusted to meet individual needs.

Usual Dosage: Syrup 1/2 to 1/4 teaspoonful every 4 hours, as needed.

Initial dose: Adults 1 - 3 ml; Children 1/2 to 1 ml.

Maximum dose: Adults 12 ml; Children 4 ml.

Caution: Do not exceed maximum dose.

DRUG INTERACTIONS: The central nervous system depressant effect of Hycotuss® Expectorant may be additive with that of other central nervous system depressants. See Warnings.

Side Effects: Of overdosage signs and symptoms. Side effects of overdosage may be characterized by respiratory depression, stupor, and coma.

See information for prescribing information.

© Endo Laboratories, Inc.

Subsidiary of E.I. du Pont de Nemours & Co., Inc.

Montgomery, Pa. 19454

Printed in U.S.A.

100 mg



Diurnal Excretion May Sift Renal from Essential Hypertension

Medical Tribune World Service

MARTIN, CZECHOSLOVAKIA—Essential hypertension may be distinguished from hypertension due to renal artery stenosis on the basis of diurnal rhythm of sodium and water excretion, according to Dr. Ota Schueck and Jaroslav Stríbrna, of the clinical pharmacology unit, Institute of Clinical and Experimental Medicine, Prague.

Both groups of patients show nocturia, the investigators reported at a meeting of the International Endocrine Society here. However, a large study has established that patients with essential hypertension excrete sodium and water at the same rate during day and night (day/night ratio of 1.0), while those with renal hypertension excrete more

sodium and water at night (day/night ratio less than 1.0). The normal ratio of day to night sodium excretion is about 1.5.

The characteristic diurnal rhythm excretion pattern remained even after treatment with reserpine, hydralazine, or other antihypertensive agents brought blood pressure down, the researchers said. Neither are diurnal rhythms affected by salt intake. Furthermore, there was no statistical relationship between levels of Na excretion, mean blood pressure, or creatinine clearance.

The data suggest that control of nocturia is at the level of tubular transport in the kidneys and unrelated to renal hemodynamics, the investigators said. They speculated that at some stage in the development of essential and

renal hypertension a resetting of tubular transport occurs that is resistant to change, even after blood pressure is reduced.



© 1975, Medical Tribune, Inc.

Wine Books

A few days ago I was lunching with a friend and an out-of-town colleague who was visiting him. Hearing that the colleague was a doctor, I asked whether he had ever read this column. He said he had, and when I asked for his comments, he mentioned several things: "There's only one thing you haven't done that I wish you would," he added. "Do a column on wine books."

Wine books can be divided into four categories: the general guides, the encyclopedias, the detailed books on specific areas, and the so-called cocktail table books which range from pictorial tours of the world's vineyard areas to pleasantly chatty discussions of wine and the wine-life.

Of the general guides, the best is probably the *Signet Book of Wine* (Signet paperback) by Alexis Bespaloff. This is a 221-page volume which passes the wines of the world through a quick but cogent review, and then considers the matters of serving, storing, ordering in restaurants, etc. Other good inexpensive books of this type are the *Vintage Wine Book* by William Leedom (Vintage), and *An Insider's Guide to Low-priced Wines* by William Massee (Dolphin). In hardcover, *Wine* by Hugh Johnson (Simon & Schuster) is top-rate, and I would recommend (if it can be found) *Wines* by Julian Street (Knopf), an old classic.

Major Encyclopedias

The first of the major encyclopedias to appear on the market was produced under the direction of Frank Schoonmaker (*Encyclopedia of Wine*, Hastings House). It is an excellent book with an emphasis on precision and consistency. Somewhat broader in scope and more designed for general readability is the *Encyclopedia of Wine and Spirits* by Alexis Bespaloff (Knopf). Recently Hugh Johnson has authored a *World Atlas of Wine* (Simon & Schuster) which combines detailed maps and an informative text. It is a rare avis.

The best way to approach the third category is by region. Fortunately a few books have surfaced as best-sellers, and these will give the reader as much detailed information as one will ever need. My recommendations would be: *The Wines of France* (Lichine, Knopf), *The Wines of Germany* (Schoonmaker, Hastings House), *The Wines of Italy* (Ray, McGraw-Hill), *The Great Wines of Italy* (Dallas, Doubleday), *Sherry and the Wines of Spain* (Rainbird, McGraw-Hill), *The Wines of Portugal* (Allen, McGraw-Hill), *The Wines of America* (Adams), *The Treasury of American Wines* (Chromian, Crown), and *The Wines, Vineyards, and Vignerons of Australia* (Simon, Lamadouche Press).

The fourth category is a buy-whatever-attracts-you area. I would recommend particularly the wine diaries of Harry Waugh. They provide excellent reading.

Wednesday, November 5, 1975

MEDICAL TRIBUNE

Wednesday, November 5, 1975

Planned Parenthood: Infarct Risk Curbs 'Pill'

Continued from page 1
same age group, for an increase of 5.7 times in relative risk.

The estimated incidence of fatal myocardial infarction in women of this age group showed a comparable spread: 11.7 per 100,000 nonusers and 54.7 per 100,000 users, with the relative risk increased 4.7 times.

Dr. Tyner thinks further research will be needed to substantiate or disprove these studies, and cautions that it is important to maintain perspective in considering risks versus benefits.

The British studies found, she noted, six risk factors more often in patients with myocardial infarction than among controls: heavy cigarette smoking, diabetes, hypertension, hypercholesterolemia, a history of pre-eclampsia toxemia, and obesity.

She believes agreement is not universal that the combined effect of these factors and the use of oral contraceptives is synergistic, but she says it is undoubtedly additive, and stresses that older women must be checked carefully for the presence of the factors.

The laboratory tests advised by Dr. Tyner would include the routine ones for all women seen at Planned Parenthood clinics: hematocrit values, testing for syphilis and gonorrhea, urinalysis, and the Pap smear.

But for the older woman, Dr. Tyner thinks that—when indicated—this battery of tests may need to be augmented to include blood cholesterol (or SMA 12), triglycerides, stress EKG, the three-hour glucose tolerance test, and

a chest x-ray (for heavy smokers). If the patient's history or laboratory findings indicate the presence of one or more high-risk factors, then Dr. Tyner says it is appropriate for the clinician to point out the potential hazard of oral contraceptives and to suggest alternate methods of family planning.

"Physicians have a right to refuse to prescribe the agents if in their best judgment—after reviewing the history, the physical, and the lab tests—they feel the patient's risk is too high," she said. "They have to be able to practice according to the dictates of their best medical judgment."

What if the patient insists on use of the oral agents?

Physicians then have three alternatives, in Dr. Tyner's opinion. One is to obtain a signed release indicating that all possible hazards have been explained and that the patient elects to use the agents and assumes full responsibility herself.

Special Lab Tests

Another is to advise the special laboratory tests, assuming that these have not already been performed, or further consultations, in order to reach a final decision on whether or not to prescribe oral agents.

The last alternative is to refer the patient elsewhere for management of contraception, "since in no case should physicians be coerced into doing something they consider medically inappropriate. Any more than patients should be coerced into actions they may not be happy with."

Dr. Taylor offered these options when oral agents seem contraindicated:

- The diaphragm, "which is familiar to many women in the older age groups and remains a good method," despite a failure rate of about 15 percent. Effectiveness can be increased to a level between that of oral agents and intrauterine devices, provided the woman uses a combination of diaphragm with a suitable jelly, foam, or cream, and the man uses a condom."

- The intrauterine device, which has a rate of effectiveness approaching that of oral agents and when used correctly is "least likely to cause serious complications." Follow-up at three months and then every year is advised.

- Sterilization, which is being elected by an increasing number of couples "particularly those in the older age groups" who have had all the children they want.



The familiar refrain of depression: morning fatigue... sadness... anorexia... insomnia

Now, Merrell offers Norpramin (desipramine hydrochloride tablets N.F.) to effectively relieve these common manifestations of depression.

Norpramin also provides additional benefits in treatment of your patients.

- effectively relieves physical, psychological and emotional symptoms of depression
- minimal daytime sedation—important for patients who must be alert to perform daytime activities
- relief that may begin in 2 to 5 days—but full therapeutic effect is seldom seen before 2 weeks
- side effects rarely require discontinuation of therapy

Prescribe Norpramin to change the familiar refrain of depression in your practice.

Norpramin*

Desipramine hydrochloride tablets N.F.

Merrell Laboratories

1000 Spring Hill Road, Kinston, NC 28501

Telephone: (910) 251-1111

Telex: 32-1111

Fax: 1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541-1111

1-800-541

"Let me tell you about the medicine I'm going to prescribe."

TALKING OVER VALIUM®(diazepam) THERAPY WITH YOUR ANXIOUS PATIENT



And it's also good for him to realize that he will be taking Valium only as long as he needs it.

Your expressed confidence in the medication prescribed, and the positive atmosphere in which therapy is given and accepted, work to the patient's advantage.

A patient often benefits by a greater understanding of his treatment program. You may find it helpful to make your patient aware that the purpose of therapy with Valium is to help reduce discomforting and disabling symptoms of excessive psychic tension and anxiety. It is beneficial for him to understand that much of his tension and anxiety can be relieved by your reassurance and counseling, and that these measures can do more than anything else to help him cope with his basic problems. The patient is reassured in knowing he can expect his medication to help him avoid feeling overwhelmed by his symptoms.

Selection of a dosage regimen is an important consideration when Valium (diazepam) is prescribed, and dosage should be individualized to achieve maximum beneficial effect. If the patient understands clearly when and how much to take, and if he knows why it's to his benefit to follow the regimen closely, the chances are better that he will take the medication precisely as directed. That should help avoid missed doses and discourage taking too much or too little medication—all of which can have an undesirable effect on the management of the patient's condition.

"It's important that you follow my directions closely."

"I'll see you again the week after next and we'll see how you're making out."

Your patient is often likely to feel reassured when you talk about seeing him again to check his progress. A planned visit evidences your continued interest and affords the patient an opportunity to report improvement he has made and to relate whatever continuing or additional difficulties he may be experiencing. It's also a chance for him to describe his response to therapy with Valium.

During follow-up visits, as your patient talks about his medication and about its effects on his symptoms, he will provide the kind of information that will be of great help in evaluating total therapy, adjusting the dosage of Valium, or discontinuing the medication entirely if that seems indicated.

Valium®(diazepam)
2-mg, 5-mg, 10-mg scored tablets
for individualized treatment of psychic tension

ROCHE

Please see the following page for a summary of product information.



Valium® (diazepam)

2-mg, 5-mg, 10-mg scored tablets

Prompt, effective action. Valium (diazepam) works rapidly to relieve pronounced psychic tension in patients overreacting to stress and in psychoneurotic patients.

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Tension and anxiety states; somatic complaints which are concomitants of emotional factors; psychoneurotic states manifested by tension, anxiety, apprehension, fatigue, depressive symptoms or agitation; symptomatic relief of acute agitation, tremor, delirium tremens and hallucinosis due to acute alcohol withdrawal; adjunctively in skeletal muscle spasm due to reflex spasm to local pathology; spasticity caused by upper motor neuron disorders; athetosis; stiff-man syndrome; convulsive disorders (not for sole therapy).

Contraindicated: Known hypersensitivity to the drug. Children under 6 months of age. Acute narrow angle glaucoma; may be used in patients with open angle glaucoma who are receiving an appropriate therapy.

Warnings: Nor of value in psychotic patients.

Caution against hazardous occupations requiring complete mental alertness. When used adjunctively in convulsive disorders, possibility of increase in frequency and/or severity of grand mal seizures may require increased dosage of standard anticonvulsant medication; abrupt withdrawal may be associated with temporary increase in frequency and/or severity of seizures. Advise against simultaneous ingestion of alcohol and other CNS depressants. Withdrawal symptoms (similar to those with barbiturates and alcohol) have occurred following abrupt discontinuance (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating). Keep addiction-prone individuals under careful surveillance because of their predisposition to habituation and dependence. In pregnancy, lactation or women of childbearing age, weigh potential benefit against possible hazard.

Precautions: If combined with other psychotropics or anticonvulsants, consider carefully pharmacology of agents employed; drugs such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other anti-

Wide margin of safety. Valium is generally well tolerated and in usual dosages rarely produces significant adverse reactions. (See prescribing information below.)

Dosage flexibility. Scored Valium 2-, 5-, and 10-mg tablets give you dosage flexibility no tranquilizer capsule can match.

depressants may potentiate its action. Usual precautions indicated in patients severely depressed, or with latent depression, or with suicidal tendencies. Observe usual precautions in impaired renal or hepatic function. Limit dosage to smallest effective amount in elderly and debilitated to preclude ataxia or oversedation.

Side Effects: Drowsiness, confusion, diplopia, hypotension, changes in libido, nausea, fatigue, depression, dysarthria, jaundice, skin rash, ataxia, constipation, headache, incontinence, changes in salivation, slurred speech, tremor, vertigo, urinary retention, blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances, stimulation have been reported; should these occur, discontinue drug. Isolated reports of neutropenia, jaundice; periodic blood counts and liver function tests advisable during long-term therapy.

Dosage: Individualize for maximum beneficial effect. **Adults:** Tension, anxiety and psychoneurotic states, 2 to 10 mg b.i.d. to q.i.d.; alcoholism, 10 mg t.i.d. or q.i.d. in first 24 hours, then 5 mg t.i.d. or q.i.d. as needed; adjunctively in skeletal muscle spasm, 2 to 10 mg t.i.d. or q.i.d.; adjunctively in convulsive disorders, 2 to 10 mg b.i.d. to q.i.d. **Geriatric or debilitated patients:** 2 to 2½ mg, 1 or 2 times daily initially, increasing as needed and tolerated. (See Precautions.) **Children:** 1 to 2½ mg t.i.d. or q.i.d. initially, increasing as needed and tolerated (not for use under 6 months).

Supplied: Valium® (diazepam) Tablets, 2 mg, 5 mg and 10 mg—bottles of 100 and 500; Tel-E-Dose® packages of 100, available in trays of 4 reverse-numbered boxes of 25, and in boxes containing 10 strips of 10; Prescription Paks of 50, available singly and in trays of 10.


ROCHE
Pfizer U.S.A. Division
Division of Hoffman-La Roche Inc.
Nutley, New Jersey 07110

Wednesday, November 5, 1975

MEDICAL TRIBUNE

By Olden

Clinical Trials



New Combined Drug Held Effective Against All Bacteria Tested

Continued from page 2 bactericidal activity. In fact, the researchers reported, PCS not only eliminates DFA self-reversal but also enhances the antimicrobial activity of both agents manyfold.

The new drug has proven equally effective when given to mice orally or by injection against a broad spectrum of bacterial species, including all the serious pathogens for man. The Merck scientists were particularly pleased that *Pseudomonas aeruginosa*, a highly resistant pathogen which is a growing problem in hospitalized patients, proved susceptible to the drug's effect.

According to Dr. Christopher M. Martin, senior director of medical affairs at Merck's research laboratories, not one bacterial strain tested so far has been resistant to the drug. He said the company was "cautiously optimistic that bacteria will have a terrible time with this drug."

Apprehension that the new agent might kill off harmless and necessary bacteria as well as virulent pathogens has been dispelled by studies in mice which show that it is absorbed into the bloodstream from the upper intestinal tract, Dr. Martin said. Bacteria in the lower tract, the mouth and the skin were unaffected.


Safety testing in human volunteers is expected to begin in early 1976, Dr. Martin announced. Monkeys receiving up to 30 times the normal human dose have exhibited no side effects. However, he cautioned, earlier cycloserine drugs also produced no side effects in animals but caused tremors, behavioral changes and convulsions in humans.

Outpatient Arteriography

Medical Tribune Report

ROCKLAND, MAINE—Outpatient arteriography could mean considerable savings in hospital fees, Drs. Peter E. Giusti and Paul J. Kilbran, of the radiology department of Knox County General Hospital, said recently. In a four-year study of 300 patients requiring arteriography, the physicians found no increase in complications and no hospital readmissions among 100 outpatients. The study contains other reports that complications arise during, or right after, arteriography.

INJECTABLE




Injection DECAZRON® Phosphate (Dexamethasone Sodium Phosphate) MSD equivalent to 0.50 mg dexamethasone phosphate per ml, in 4 ml and 10 ml disposable syringes and 1-ml, 5-ml, and 25-ml vials.

INGESTIBLE



Tablets DECAZRON® (Dexamethasone) MSD 0.75 mg. in bottles of 100, 250, 500, 1000 (package of 12).

BREATHABLE




RESPIHALER® DECAZRON® Phosphate (Dexamethasone Sodium Phosphate) MSD contains dexamethasone phosphate equivalent to 0.05 mg dexamethasone phosphate or 0.084 mg dexamethasone. Dose: 0.05 mg dexamethasone phosphate or 0.084 mg dexamethasone phosphate, as propellants, and alcohol 2%, in 12.5 g cartridge, 12.5 g aerosol, 170 sprays and refill cartridge.

DROPPABLE



Sterile Ophthalmic Solution DECAZRON® Phosphate (Dexamethasone Sodium Phosphate) MSD 0.1% solution equivalent to 0.1 mg dexamethasone phosphate per 1-ml bottle. Ocular Dispenser and 2.5 ml dropper bottles.

SPREADABLE



Topical Cream DECAZRON® Phosphate (Dexamethasone Sodium Phosphate) MSD 0.1% cream equivalent to 0.1 mg dexamethasone phosphate per gram. 15 g and 30 g tubes.

SPRAYABLE



Topical Aerosol DECAZSPRAY® (Dexamethasone) MSD 10 mg per 50-g container. TURBINAIR® DECAZSPRAY (Dexamethasone Sodium Phosphate) MSD equivalent to approximately 0.1 mg dexamethasone phosphate per 12.5 g cartridge. 0.05 mg dexamethasone phosphate per metered spray in 12.5 g cartridge delivering 170 sprays.

DECADRON® (DEXAMETHASONE) MSD

New Suspension DECAZRON-LAC® (Dexamethasone Acetate) MSD equivalent to 0.5 mg dexamethasone per ml, in 5-ml vials.

**IN
CONSULTATION**
Continued from page 13

enclosed by their inability to switch back to eye glasses. Changes induced in the cornea by hard lens wear may make the acuity through eye glasses changeable and unsatisfactory for long periods of time after the hard lenses are removed. Experience has shown that complications such as spectacle blur or abrasion occur much less frequently with soft than with hard contact lenses.

Certainly, soft contact lenses are less durable than hard lenses. However, since soft lenses cling to the eye better than the hard ones, they are much less likely to fall out accidentally, not a rare occurrence with hard lenses. Statistics have reported between 23 and 40 per cent of hard contact lens wearers lose one or both of their lenses within the first six months. Of even greater importance is the fact that most of the instances of corneal abrasion, irritation, or spectacle blur are produced by a warped, scratched, old, hard contact lens. Both hard and soft contact lenses should be replaced periodically to let the lens wearer benefit from new materials or improvements in technology, and to avoid the damage that can be caused by warped or scratched hard lenses or old soft lenses that have become coated with mucus. It is better not to save the patient's money than to risk potential damage to the eye.

The heat sterilization method employed by one manufacturer of soft lenses and the cold, hydrogen peroxide sterilization procedure employed by another are both extremely safe and effective, with no incidence of clinical bacterial infection certainly not greater than that found in hard contact lenses and perhaps approaching that found in individuals wearing spectacles.

Is there any advantage or disadvantage in having both spectacles and contact lenses?

Eye glasses are the safest, most effective device for the correction of refractive errors. Every contact lens patient should have a pair of spectacles that provide best visual acuity so as to enable free alternation with contact lenses. In addition, when the wearer of hard lenses does put on regular eye glasses and is unable to see clearly, this may be an indication of spectacle blur requiring attention.

A contact lens wearer should be able to switch to eye glasses as necessary for correction and/or comfort, elimination of glare or difficulty seeing at night, or when there are problems of visual acuity, conjunctivitis, irritation, or other complications.

Next In Consultation

DR. JAMES M. STENGLE, Deputy Director for Medical Affairs, Lister Hill National Center for Biomedical Communications, N.I.H., and Chairman, Medical and Scientific Advisory Council, National Hemophilia Foundation, will discuss what's new and important in hemophilia.

SLEEPING BETTER... THE BEGINNING OF THE END OF CLINICAL DEPRESSION/ANXIETY

Even before it helps her clinical depression/anxiety, Sinequan® (doxepin HCl) can help her sleep through the night.

The sedative effect of Sinequan usually helps clinically depressed/anxious patients with accompanying sleep disturbances fall asleep more easily, remain asleep, and awaken more rested.

Administering the major portion of the daily dose *h.s.* generally obviates the use of supplementary hypnotic agents.

The marked anti-anxiety property of Sinequan is particularly helpful in relieving apprehension, tension and worry. Optimal antidepressant effect is usually seen two to three weeks after initiation of therapy.

SINEQUAN® DOXEPIH HCl

10 mg. tablet or 100 mg. capsules.

BRIEF SUMMARY
Sinequan® (doxepin HCl) Capsules

Contraindications: Sinequan is contraindicated in individuals who have shown hypersensitivity to the drug.

Sinequan is contraindicated in patients with glaucoma or a tendency to urinary retention.

Warnings: Use in Pregnancy: Sinequan has not been studied in the pregnant patient. It should not be used in pregnant women unless, in the judgment of the physician, it is essential for the welfare of the patient, although antihistaminic effects have not resulted in any teratogenic effects.

Usage in Children: The use of Sinequan in children under 12 years of age is not recommended, because side conditions for its use have not been established.

MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors. Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with Sinequan (doxepin HCl). The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage of the drug.

Sinequan: In contradistinction to patients with glaucoma or a tendency to urinary retention.

Other: Use in the elderly: Although doxepin (Sinequan) has been reported to cause confusion and hallucinations in the elderly, it is not clear whether this is due to the drug or to the underlying disease process. At the present clinical dosage, 75 to 150 mg. per day, Sinequan can be given concomitantly with guanethidine and related compounds without blocking the related compounds without blocking the antihypertensive effect. At doses of 300 mg. per day or above, Sinequan does exert a significant blocking effect.

Significant improvement has occurred, particularly in the early course of therapy.

Although Sinequan (doxepin HCl) has significant tranquilizing activity, the possibility of activation of psychotic symptoms should be kept in mind.

Other structurally related psychotomimetic agents (e.g., imidocarbazine and dibenzocycloheptene) are capable of blocking the effects of guanethidine and similar acting compounds in both the animal and man. Sinequan, however, does not show this effect.

Precautions: Since drowsiness may occur with the use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking this drug.

Patients should also be cautioned that their response to alcohol may be potentiated.

Since drowsiness is an inherent risk in any depressant product and may remain so until

Sinequan (doxepin HCl) was similar to the other structurally related psychotherapeutic agents as regards its ability to potentiate mesophenylamine response in the animal. However, in the human this effect was not seen. This is in agreement with the low incidence of the side effect of tachycardia seen.

Adverse Reactions: **Anticholinergic Effects:** Dry mouth, blurred vision, and constipation have been reported. They are usually mild, and often resolve with continued therapy or reduction in dose.

Drowsiness: Drowsiness is a common initial side effect. This usually occurs early in the course of treatment, and tends to disappear as therapy is continued.

Cardiovascular Effects: Tachycardia and hypertension have been reported infrequently.

Other: **Central Nervous System Effects:** Drowsiness has been observed. This usually occurs early in the course of treatment, and tends to disappear as therapy is continued.

Gastrointestinal Effects: Gastritis, nausea, vomiting, diarrhea, constipation, and abdominal cramps have been reported.

Endocrine Effects: Endocrinological changes have been reported.

include extrapyramidal symptoms, gastrointestinal reactions, secretory effects such as increased sweating, weakness, dizziness, fatigued, weight gain, edema, paresthesias, tinnitus, chills, tinnitus, photophobia, decreased libido, rash, and pruritus.

Dosage: For most patients with illness of mild to moderate severity, a starting dose of 25 mg. t.i.d. is recommended. Dosage may subsequently be increased or decreased at appropriate intervals and according to individual response. The usual optimum dose range is 75 mg./day to 150 mg./day.

In more severely ill patients an initial dose of 50 mg./day may be required with subsequent gradual increase to 300 mg./day if necessary. Additional specific effect is rarely to be obtained by exceeding a dose of 300 mg./day.

In patients with very mild symptomatology: More detailed professional information available on request.

LISTER LABORATORIES DIVISION
Pfizer Inc.
© 1974 Pfizer Inc.

**IMMATERIA
MEDICA**
**For the President
Who Has Nothing**

It may be that the President of your favorite medical society, country or club has everything, but just in case you're looking for something, we call your attention to an ad in the Miscellaneous column of the *Wolf Street Journal*, sandwiched in between a peat moss ad (200,000 yards) and one for antique hallmarked British silver flatware:

MISCELLANEOUS

PERIODICAL PRESIDENTIAL
PRIVATE RAILWAY CAR
AVAILABLE FOR RENTAL
A short or long term lease.
Inquiries to be made to Ober-
laire, Ltd., 200 Madison Ave-
nue, New York City, 10016.
(212) 585-1862

The short-term lease idea looked mighty attractive.

Tut-tutted Again

We've been tut-tutted again by Dr. Sam Nixon of Floresville, Texas, because we referred to *The Education of H.Y.M.*E K*P*L*A*N* rather than *H.Y.M*A*N*, which is the way Dr. Sam correctly remembers it.

Our trouble is that we affectionately remember Hyman as Hymic. What can we say? It won't be the first time that affection has led us to err.

But if we may, we'd like to send up a cheer for Leo Rosten who discovered Hymic. Bronx-born and bred, and so huddled-up for a tiny bit of recognition that he decorated his name with asterisks. It was probably the most expressive use of typography since e e cummings read archy and mehitabel in *Don Marquis' column*. Least this be considered an "inside" joke accessible only to aging physicians (over 50), we will explain that archy was a cockroach whose physical limitations made it impossible for him to use the typewriter shift key for capitals and punctuation. It was archy who, in orv's new *dear*, said:

*there is bound to be a certain amount
of trouble running any country
if you are president the trouble happens
to you
but if you are a tyrant you can orange
things so
that most of the trouble happens to
other people*

